AliveCor QT Service vs EchoNext
AI Verdict
Choose AliveCor QT Service if…
Choose AliveCor QT Service if your primary concern is assessing cardiac safety related to medication management, particularly for drugs known to prolong the QT interval. This cloud-based SaMD provides instant, accurate QT and QTc measurements from AliveCor 6-Lead ECGs, enabling healthcare professionals to make informed prescribing decisions and monitor patients for potential life-threatening arrhythmias like Torsades de Pointes. It is ideal for streamlining the process of screening for QT prolongation in an office setting or remotely, reducing treatment delays and enhancing patient safety.
View AliveCor QT Service →Choose EchoNext if…
Choose EchoNext if your goal is to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard 12-lead ECGs. This FDA-cleared AI tool is designed to identify patients who may have underlying structural heart issues that would otherwise go undetected until symptoms appear, prompting further evaluation with an echocardiogram. It is particularly well-suited for broad access in various clinical settings, from major hospitals to community practices, to facilitate earlier diagnosis and potentially life-saving treatment for millions affected by structural heart disease.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AliveCor QT Service | EchoNext |
|---|---|---|
| Pricing | Contact vendor for pricing details. | Starts at $600/month |
| Deployment | Cloud-based (Software as a Medical Device). Accessed over the internet. | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AliveCor QT ServiceAliveCor QT Service leverages the KardiaMobile 6L, a handheld device that allows patients to record their own ECGs, which can then be uploaded for analysis. This patient-centric approach and ease of use in various settings (including remote and resource-limited) suggest higher usability.
Clinical Value
EchoNextEchoNext demonstrates superior clinical value by detecting a broader range of critical and often hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. Studies show it outperforms cardiologists in accuracy for these detections.
Pricing & Value
EchoNextEchoNext provides transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts. AliveCor QT Service requires contacting the vendor for pricing, making its cost less transparent. While specific feature-for-feature value is hard to compare without detailed pricing from AliveCor, EchoNext's clear pricing structure offers better transparency.
Enterprise Readiness
AliveCor QT ServiceAliveCor QT Service offers an API for integration with various healthcare platforms like EHR, SDK, CRM, EDC, and PSP, indicating a strong focus on enterprise integration. It also has a robust enterprise platform for managing patient heart conditions. EchoNext is available through the OpenEvidence platform, but its direct enterprise integration capabilities are less detailed.
Innovation
EchoNextEchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect a wide range of *hidden* structural heart diseases from standard ECGs, conditions traditionally requiring more expensive and less accessible imaging. This expands the diagnostic capability of a routine test. AliveCor QT Service, while innovative in its mobile QT measurement, focuses on a more specific, albeit important, aspect of cardiac safety.
Support & Docs
TieBoth tools are FDA-cleared and HIPAA compliant, suggesting a commitment to regulatory standards and data security. However, specific details regarding the breadth and depth of their support resources and documentation (e.g., user manuals, training programs, dedicated support teams beyond general contact information) are not extensively provided in the given information or readily available through general web searches for either product.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AliveCor QT Service | EchoNext |
|---|---|---|
| Tool Name | AliveCor QT Service | EchoNext |
| Company | AliveCor | Pathway Labs |
| Description | A cloud-based Software as a Medical Device (SaMD) that provides instant, accurate QT and QTc interval measurements from AliveCor 6-Lead ECGs, enabling healthcare professionals to assess cardiac safety and inform medication prescribing decisions. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Functionality | Measures QT and QTc intervals (Bazett's and Fridericia's formulas) from AliveCor 6-Lead ambulatory ECG devices. | Analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
Videos
Demos, reviews, and walkthroughs featuring AliveCor QT Service and EchoNext.
Frequently Asked Questions
More Comparisons
More matchups featuring AliveCor QT Service or EchoNext
Backers
Who funded each tool's parent company.